Additional Relevant Details
Poster A013: Favorable changes in the tumor microenvironment following intravenous dosing with live attenuated Listeria monocytogenes-based immunotherapy.
In a poster session on Sunday, September 25, 2016, Meredith Leong, Ph.D., a scientist at Aduro, presented data from multiple preclinical studies using Aduro’s LADD immunotherapy platform. The data demonstrated that a combination of LADD with an anti-PD1 checkpoint inhibitor results in improved anti-tumor efficacy in multiple tumor models. In addition, analyses of biopsies from patients given CRS-207, a LADD immunotherapy, showed enhancement of infiltrating CD8+ T cells, mature dendritic cells, macrophages and natural killer cells, all specialized immune system cells involved in eradicating tumor cells. Consistent with this clinical data, the preclinical findings showed that LADD induced a potent favorable change in the tumor microenvironment including increased CD8+ T cells, infiltration of neutrophils, and a reduction of regulatory T cells, creating an environment for the tumor susceptible to anti-cancer treatments.Poster B020: STING activation in the tumor microenvironment using a synthetic human STING-activating cyclic dinucleotide induces potent anti-tumor immunity
In a poster session on Monday, September 26, 2016, Sarah McWhirter, Ph.D., a scientist at Aduro, presented preclinical data on ADU-S100, a STING Pathway Activator. The data demonstrate that ADU-S100 stimulates the production of interferon-beta by all human STING alleles. Importantly, the results showed that injecting ADU-S100 directly into the tumor microenvironment induced T cells with tumor-specific antigenic repertoire leading to durable anti-tumor immunity. In addition, the combination of STING activation in the tumor microenvironment and PD-1 blockade enhances antitumor efficacy. There is an ongoing Phase 1 first-in-human clinical study to evaluate the safety, tolerability and possible anti-tumor activity of ADU-S100 in patients with cutaneously-accessible advanced metastatic solid tumors or lymphomas.